Following a standardized general anaesthetic for total abdominal hysterectomy, patients received either patient controlled analgesia (PCA) with morphine 1 mg/ml (group M, n=33) or morphine 1 mg/ml plus ketamine 2 mg/ml (group K, n=37) for 48 hours in a randomized, double-blind fashion. In 43 women the area of allodynia around the scar was mapped as a measure of the degree of central sensitization.
Although the aetiology of postoperative nausea and vomiting after gynaecological surgery is multifactorial, postoperative analgesia with opioids is thought to be a significant factor. Internal audit at our institution indicates it is particularly common after total abdominal hysterectomy, with an incidence of up to 25%.
A study published in 1996 1 suggested that adding ketamine to morphine patient-controlled analgesia (PCA) was beneficial because of significantly reduced opioid usage and opioid related side-effects. However the nature of the surgery, namely microdiscectomy, raised some concern about the clinical significance of this effect. The effect may not have been due to modulation of N-methyl-D-aspartate (NMDA) receptors 2 as the stimulus was principally nociceptive rather than neuropathic and only of moderate intensity.
We decided to study the effect of combined morphine-ketamine PCA for postoperative analgesia after total abdominal hysterectomy. Our aims were: (a) to establish whether such a combination would result in a reduction in morphine use and related side-effects, and (b) whether there would be a reduction in central sensitization, as determined by the area of allodynia around the surgical incision.
MATERIALS AND METHODS
Following approval of the study by the Area Ethics Committee, and having obtained informed consent, patients presenting for total abdominal hysterectomy were randomized in a double-blind fashion to receive either PCA morphine 1 mg/ml (group M) or PCA morphine 1 mg/ml and ketamine 2 mg/ml (group K) after a standardized general anaesthetic.
All patients presenting for total abdominal hysterectomy were considered eligible except those receiving opioids preoperatively; undergoing surgery for malignancy, with a history of a psychiatric illness or delirium, and of ASA grade greater than 2 at preoperative assessment.
Apart from the study drugs, all patients received identical treatment. The use of the PCA pump and scoring with a Visual Analog Scale (VAS) were explained during the preoperative visit. After gaining intravenous (IV) access and commencing a crystalloid infusion, a standardized general anaesthetic was performed. This comprised induction with propofol, muscle relaxation with vecuronium and intraoperative analgesia with IV morphine (up to 0.2 mg/kg). Anaesthesia was maintained with air/oxygen/isoflurane and reversal of muscle relaxation achieved with neostigmine and atropine. Boluses of morphine were given in recovery as required prior to PCA (1 ml bolus and five-minute lockout interval). PCA was commenced on return of cognitive function. Patients were charted prochlorperazine 6.25 mg IV every six hours as required, and ondansetron 4 mg IV twice daily as required, as rescue antiemetic. Diazepam 2.5 mg orally was prescribed for dysphoria, and promethazine 12.5 mg IV or intramuscular (IM) ordered for pruritus.
Randomization was achieved using computergenerated groups and a sealed envelope system. The patient, anaesthetist and Acute Pain Service (APS) personnel were unaware of the allocation. Recovery room staff, who had access to the randomization schedule and could also break the code in event of an emergency, prepared all solutions.
Because the use of the Von Frey hairs requires some time to master, for the purpose of consistency all measurements were done by one of the investigators (GD) who was blinded to group allocation. It was intended to enrol 50 patients in this manner as a pilot study, however only 43 were recruited because GD left the department before this target was reached. These patients were analysed first, and a power calculation was performed as detailed in the statistical section below.
The first 43 patients had the area of allodynia around their incision measured on day 2. This was achieved by mapping the response to a 4.56 Newton Von Frey hair at 2cm intervals along the incision 3 . These points were then joined to form a polygon, reproduced on graph paper and scanned using a Power Macintosh 7100 and a Microtek Scanmaker 2 scanner. The area was measured using National Institute of Health "Image" software.
The study period was defined as either 48 hours post hysterectomy or until the cessation of PCA, if this occurred first. The decision to cease PCA prior to 48 hours could only be made by the patient and the surgeon (both of whom were unaware of group allocation) on the basis that they felt PCA was no longer indicated. The criteria for such withdrawal were patient request, uncontrolled nausea and/or vomiting or uncontrolled pruritus. All patients were assessed during the daily APS ward round on the first and second mornings after surgery. Data collected were intraoperative morphine dose, bolus dose given in recovery prior to commencement of PCA, total dose of morphine at 48 hours or cessation of PCA, visual analog scores (VAS) for pain at rest and on coughing, and VAS for nausea and patient satisfaction. Patients were questioned directly about the presence of dysphoria or pruritus.
A power calculation performed after the first 43 patients were analysed determined that a case sample size of 31 per group was adequate to demonstrate a difference of 2.5 in VAS on coughing with a power of 90% and an α of 0.05. Histograms of the frequency distributions for data obtained showed that the data were not normally distributed, and hence nonparametric testing was used for statistical analysis. Height and weight were assumed to be normally distributed, and were analysed using unpaired t tests. Between-group comparisons were made using the Mann-Whitney test and the correlation between scar length and area of allodynia analysed with Spearman's Rank Correlation test. Fisher's exact test was used to compare the numbers of patients withdrawn from each group.
RESULTS
Seventy women were enrolled (group M, n=33 and group K, n=37). The women in whom the area of allodynia was measured were the first 42 patients recruited (group M, n=18 and group K, n=24). One patient (group M) developed a wound infection and was withdrawn, leaving 17 patients in group M for the purpose of analysis ( Table 1) . All patients were included in the efficacy analysis, whether they completed 48 hours of PCA, were withdrawn because of side-effects, or ceased PCA before 48 hours postoperatively.
There were no significant differences between the groups with respect to age or weight. This was also true for the subgroups where area of allodynia was measured, in which two other variables, patient height and length of incision, were also not significantly different ( Table 1) .
Thirty women used PCA for the entire 48 hours (group K, n=10; group M, n=19), 29 ceased PCA prior to 48 hours (group K, n=16; group M, n=13), and 11 were withdrawn because of side-effects (group K, n=10; group M, n=1, P=0.006, Table 2 ). There was a significant difference in the length of time each group used PCA (P=0.003). The total dose of PCA was not significantly different ( Table 3) .
The median (IQR) area of allodynia in the group M subset was 57 (82) cm 2 . In group K, the median (IQR) area was 42 (57) cm 2 (P=0.04).
Pain score data and hourly drug consumption are summarized in Table 4 .
No statistical differences were found for pain scores or hourly drug use except for a significant difference between pain scores on coughing on day 1.
There were no significant differences between the groups for patient satisfaction ( Table 5 ). Patients in both groups were satisfied with their analgesia despite high pain scores.
There were no significant differences between groups for nausea scores or antiemetic usage. One patient in group M and 2 in group K stopped PCA before the end of the study period because of uncontrolled nausea ( Table 6 ).
A total of 10 patients in group K were withdrawn, as per protocol, as a result of uncontrolled sideeffects (dysphoria n=4, nausea n=2, pruritus n=4) compared with 1 in the group M (nausea n=1)(P=0.006). Hourly doses in these patients who were withdrawn ranged from 0.5 to 3.9 ml/h and this did not differ from all patients in group K.
DISCUSSION
We postulated that ketamine would block NMDA receptors, so reducing the central sensitization after surgery, and produce opioid-sparing effects. The latter did not prove to be the case. There are three important findings from our study, namely that ketamine in the dose used did not produce a morphine- Group M (n=33) 2.5 (5.5) 0 (1.5) Group K (n=37) 4 (7) 0 (2) Values are median (interquartile range). sparing effect; that the addition of ketamine to intravenous morphine PCA increased the incidence of side-effects to an unacceptable level; and that ketamine reduced the area of allodynia around the surgical wound (although the clinical significance of this finding is uncertain). In addition, there was a significant difference between the groups in pain on coughing on the first postoperative day, but we consider this was not of clinical significance because the size of the effect was very small. The duration of PCA use in those ceasing PCA prior to 48 hours was significantly different, with the ketamine group having a shorter duration of PCA, although again the difference was small and the clinical significance unclear.
These findings are similar to those of others [4] [5] [6] [7] [8] [9] [10] . An inappropriate pain model may explain the negative findings of some of these studies. Clinical effects of NMDA blockade may only become apparent where sufficient nociceptive stimulation has occurred to cause the ligand gated channel to open 2 . Thus, other studies can be criticized on the grounds that they examined patient groups with low levels of pain 1, [9] [10] [11] . The severity of the initial pain may thus be relevant in two ways, because if it is too mild, all drugs including placebos will prove equally efficacious 12 . This may also explain why ketamine is less effective against acute or phasic pain than it is against neuropathic pain 2, 13 .
Our study used a group of patients having abdominal hysterectomy, a moderately painful procedure, chosen because the surgical technique is fairly standardized. A number of the studies which found a benefit from the combination of NMDA antagonists and opioids investigated, or included, patients having this procedure. Our finding of a reduction in the area of secondary hyperalgesia in group K supports the notion that NMDA channels were involved in pain perception. The technique used to assess this has been previously validated 3, 14, 15 . A similar study using a lower dose of ketamine also failed to demonstrate a useful clinical effect, however it did not confirm an effective blockade of NMDA receptors 16 .
Other studies where a beneficial effect was found from the addition of ketamine may help explain our negative findings. We did not commence ketamine preoperatively, and opioids delay the onset of NMDA receptor activation rather than prevent it completely 17 . It is intuitively attractive then to suggest that ketamine should be used pre-emptively and numerous papers have claimed a pre-emptive effect of ketamine [18] [19] [20] [21] [22] [23] , although many failed to demonstrate this [7] [8] [9] [10] . However, many studies reporting opioidsparing effects did not use preoperative ketamine either, so this is unlikely to be the complete explanation.
Our study design might be of importance in explaining the lack of a useful clinical effect. Adriaenssens et al 24 delayed starting a ketamine infusion until VAS pain scores in the recovery room had reached 4, because they considered this level was required to activate NMDA receptors. They suggested the morphine-sparing effect when a continuous infusion of ketamine was added to PCA morphine may have been due to this strategy, but like other investigators claiming similar results to Adriaenssens, we did not employ this technique.
A further criticism of our design is that we did not collect data on incremental morphine consumption. Stubhaug et al studied 20 living kidney donors in a randomized double-blind placebo-controlled trial 3 . Patients in the study group received 0.5 mg/kg ketamine as a preoperative IV bolus, followed by a continuous IV infusion at 2 µg/kg/min for 24 hours and then 1 µg/kg/min for 48 hours. PCA morphine consumption was reduced in the ketamine group, but only in the first six hours postoperatively. The authors suggested this was not unexpected and due to modification of the pain intensity in the placebo group by increased morphine usage, which masked possible intergroup differences because of wide interindividual variations in opioid requirements. However Adriaenssens 24 found that cumulative and incremental morphine consumption was similar in both their groups during the first 12 postoperative hours.
An extension of the comments by Stubhaug et al that has received little attention is the influence of the type of pain on the efficacy of ketamine. They stated that the aim of their low-dose ketamine regimen was not to abolish acute pain transmitted by normal nociceptive pathways, but to remove "pathological" pain. It is possible that abdominal hysterectomy represents a predominantly nociceptive pain model, as compared with some other types of surgery. This idea is supported by the results of Wilder-Smith et al, who found fentanyl of equal efficacy to ketamine in suppressing spinal excitation after abdominal hysterectomy 6 . Thoracotomy and amputation are both known to result in a high incidence of postoperative neuropathic pain 25, 26 and may well represent a more appropriate population of patients in which to try to demonstrate additive effects of NMDA receptor antagonists and opioids. This population also offers the chance to address the clinically important issue of prevention of postoperative pain by control of early acute pain.
Our results differ from most reports in the literature in that we recorded clinically significant sideeffects despite a relatively low rate of IV ketamine (median dose 3.6 mg/h). Most studies have found a lower incidence of nausea, vomiting and pruritus with ketamine and a similar or lower incidence of dysphoria. Side-effects, particularly dysphoria, are dose-related 27, 28 . This was confirmed by Edwards et al, the only investigators to have attempted a dosefinding approach to morphine-ketamine combinations. They found increasing dysphoria as ketamine dose increased from 5 to 20 mg/h 4 . By using ketamine boluses via the PCA pump rather than a separate continuous infusion, we may have exposed our patients to an increased risk of side-effects. Others employing this technique did not find more sideeffects 1, 16 , although their hourly dose rates of ketamine were lower (< 1.5mg/h). We chose a concentration that we anticipated would lead to approximate total dose ranges which have been suggested for achieving a useful therapeutic effect from a ketamine infusion 29 .
In this study, the combination of morphine and ketamine delivered by intravenous PCA pump did not reduce hourly opioid requirements when compared to PCA morphine alone. It was associated with an unacceptably high incidence of nausea, pruritus and dysphoria, rather than a reduction in side-effects. A significant reduction in the area of allodynia around the incision was demonstrated, but this appears to have had little clinical impact. These findings differ from most previous reports, and may reflect the choice of surgery producing a primarily nociceptive type of pain and the use of a bolusing technique rather than an infusion. A more promising direction for future research might lie in determining the role of a combination of NMDA antagonists and opioids in clinical models where neuropathic pain is more likely to be present.
